On the afternoon of April 9th, 2024, the Peking University CGT (Cell and Gene Therapy) Commercialization of Scientific and Technological Achievements and Startup Model Forum was successfully held, with the theme "Enhancing the Value of CGT Achievements Transformation and Best Startup Models Discussion." The event was hosted by Peking University Office of Science and Technology Development, Business Affairs Management Office/Technology Transfer Office of Peking University Health Science Center, organized by Peking University Shanghai Lin-gang International Science and Technology Innovation Center (PKU-IICSH), Shanghai Yanyuan Private Equity Fund Management Co., Ltd. (Yanyuan Fund), and Guojian Capital, and supported by Union of Finance Alumni of Peking University and Peking University Entrepreneur's Training Camp. Pharnexcloud, Jingtian & Gongcheng, Bioshare Medical, and Elixir Clinical Research Co., Ltd. (ECR Global) provided support, while the Bank of China Beijing Haidian Sub-Branch sponsored the event.
Xiao Yuan, Vice President of Peking University Health Science Center and Chairman of PKU-IICSH, Yao Weihao, Head of Office of Science and Technology Development (OSTD) at Peking University and Director of PKU-IICSH, attended the forum and delivered speeches. Wang Guoliang, General Manager of SINOPHARM Financial Leasing Co., Ltd. attended the forum. The event was hosted by Zhang Weiwei, Deputy Director of PKU-IICSH and Assistant Director of Technology Transfer Department at Peking University Office of Science and Technology Development.
During the thematic exchange session, Xiang Wangzhongjian, General Manager of Pharnexcloud Digital Technology Co., Ltd., gave a presentation titled "The Quality of Project Initiation Determines the Quality of Results." Starting from insights into the history of biomedical innovation technology, he shared how to conduct evaluations of innovative drug project initiation systems, key points when analyzing data in CGT, innovative trends, and insights into project initiation.
Li Yingqi, Jingtian & Gongcheng Intellectual Property Partner, combined her own experience and industry expertise to thoroughly dissect the "Intellectual Property Layout Preparation and High-Value Patent Design Throughout the R&D Process" from two aspects: "Patent Mining and Layout" and "FTO (Freedom To Operate)."
Zhong Yunpeng, General Manager of Bioshare Central Laboratory and Senior Engineer analyzed "How laboratory research smoothly transitions to industrialized preclinical studies" using the development of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) products as an example. He delved into the progress, challenges, and development trends of CGT research and development.
Gong Yuntao, the CMO (Chief Marketing Officer) of Elixir Clinical Research Co., Ltd. (ECR Global), combined rich data and cases to engage with guests in a discussion on "Common Issues in Clinical Development of Biopharmaceutical Innovations." Starting from the rapid development of the Chinese biopharmaceutical industry, they brought in key success factors and case analyses in clinical development, backed by abundant data on clinical development success rates.
Gao Song, Partner of Guojian Capital, summarized industry insights and entrepreneurial experiences, presenting a theme titled "Enhancing the Quality and Value of Outcome Transformation, 20 Considerations for Entrepreneurial Readiness, and Initial Financing Planning."
Finally, Luan Yupeng, the private banker of the Bank of China Beijing Haidian Sub-Branch, gave a presentation on "Comprehensive Service Solutions for Bank of China Entrepreneur Office," introducing the services that Bank of China can provide for commercialization of achievements and the "Entrepreneur Office."
The forum brought together more than 100 experts, scholars, entrepreneurs, investors, and other industry elites in CGT, establishing a high-level communication platform to jointly explore new paths and models for the commercialization of scientific and technological achievements in this field. We look forward to promoting the deep integration of technology and economy, accelerating the commercialization and application of scientific and technological achievements in CGT.
